Sign In
Buy SKYE
$0.770
+0.0563 (+7.89%)
At Close: Jun 03, 2026
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
12:15pm, Friday, 23'rd May 2025
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Skye Bioscience to Participate in Upcoming Investment Conferences
07:00am, Thursday, 22'nd May 2025
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and othe
Arecor shares jump 10% on obesity drug partnership with Skye Bioscience
06:41am, Monday, 19'th May 2025
Shares in Arecor Therapeutics PLC (AIM:AREC) rose 10% in morning trading after the company announced a new development deal with US biotech group Skye Bioscience to improve the formulation of a mid-st
Arecor partners with Skye Bioscience to improve formulation of obesity drug
05:43am, Monday, 19'th May 2025
Arecor Therapeutics PLC (AIM:AREC) has entered a development partnership with Skye Bioscience Inc (NASDAQ:SKYE), a US-based biotechnology group, to create a more concentrated formulation of an experim
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
05:00am, Monday, 19'th May 2025
Proprietary formulation technology being applied to potentially enhance properties of nimacimab Proprietary formulation technology being applied to potentially enhance properties of nimacimab
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 13'th May 2025
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic he
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunaba
Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript
07:20pm, Friday, 09'th May 2025
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President & Chief Executive
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
04:01pm, Thursday, 08'th May 2025
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that mod
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
07:00am, Wednesday, 07'th May 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and othe
Skye Bioscience to Participate in May Investment and Medical Conferences
07:00am, Tuesday, 29'th Apr 2025
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and ot
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:06pm, Friday, 25'th Apr 2025
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
07:50am, Wednesday, 16'th Apr 2025
Weight loss drug stocks like Novo Nordisk have dropped significantly lately. This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's nimaci
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models
03:42pm, Tuesday, 15'th Apr 2025
Skye Bioscience, Inc. SKYE stock is trading higher on Tuesday with a strong session volume of 18.49 million compared to the average volume of 196.131k, as per data from Benzinga Pro.
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
07:00am, Tuesday, 15'th Apr 2025
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates superi
